TOSEDOSTAT PLUS LOW DOSE CYTARABINE COMBO INDUCES A HIGH RATE OF RESPONSES THAT CAN BE PREDICTED BY GENETIC PROFILING IN AML: FINAL RESULTS OF A PHASE II MULTICENTER STUDY

被引：0
|
作者：
Visani, G. [1 ]
Loscocco, F. [1 ]
Fuligni, F. [2 ]
Zuffa, E. [3 ]
Sensi, A. [4 ]
Zaccaria, A. [3 ]
Musuraca, G. [5 ]
Giannini, B. [4 ]
Lucchesi, A. [5 ]
Fabbri, F. [5 ]
Mianulli, A. M. [6 ]
Tosi, P. [6 ]
Tonelli, M. [4 ]
Candoni, A. [7 ]
Fanin, R. [7 ]
Sparaventi, G. [1 ]
Gobbi, M. [8 ]
Clavio, M. [8 ]
Rocchi, M. [9 ]
Piccaluga, P. [2 ]
Isidori, A. [1 ]
机构：
[1] Hematol & Stem Cell Transplant Ctr, AORMN, Pesaro, Italy
[2] Univ Bologna, S Orsola M Malpighi Hosp, Dept Expt Diagnost & Specialty Med, Hematopatol Sect, Bologna, Italy
[3] Ravenna Hosp, Hematol, Ravenna, Italy
[4] Ctr Serv Lab Unico AVR, Genet Med, Pievesestina Di Cesana, Italy
[5] IRST Meldola, Oncohematol, Meldola, Italy
[6] Rimini Hosp, Hematol, Rimini, Italy
[7] Azienda Osped Univ S Maria Misericordia, Ctr Trapianti & Terapie Cellulari Carlo Melzi DIS, Clin Ematol, Udine, Italy
[8] Univ Genoa, Hematol, Genoa, Italy
[9] Univ Urbino, Inst Biomath, I-61029 Urbino, Italy
来源：
HAEMATOLOGICA | 2015年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P564
引用
收藏
页码：215 / 215
页数：1
相关论文
共 44 条
  • [31] Bemcentinib (Oral AXL Inhibitor) in Combination with Low-Dose Cytarabine Is Well Tolerated and Efficacious in Older Relapsed AML Patients.Updates from the Ongoing Phase II Trial (NCT02488408) and Preliminary Translational Results Indicating Bemcentinib Elicits Anti-AML Immune Responses
    Loges, Sonja
    Sutamtewagul, Grerk
    Heuser, Michael
    Chromik, Joerg
    Kapp-Schwoerer, Silke
    Crugnola, Monica
    Di Renzo, Nicola
    Lemoli, Roberto M.
    Mattei, Daniele Giovanni
    Ben Batalla, Isabel
    Hellesoy, Monica
    Waizenegger, Jonas
    Janning, Melanie
    Imbusch, Charles D.
    Beumer, Niklas
    Rayford, Austin
    Nautiyal, Jaya
    Berkman-Gottlieb, Tzivia
    Micklem, David
    Gabra, Hani
    Gorcea-Carson, Claudia
    Lorens, James B.
    Fiedler, Walter
    Alvarado, Yesid
    Gjertsen, Bjorn T.
    Rieckmann, Lisa-Marie
    BLOOD, 2021, 138
  • [32] Phase I/II Study of Volasertib (BI 6727), an Intravenous Polo-Like Kinase (Plk) Inhibitor, in Patients with Acute Myeloid Leukemia (AML): Results From the Randomized Phase II Part for Volasertib in Combination with Low-Dose Cytarabine (LDAC) Versus LDAC Monotherapy in Patients with Previously Untreated AML Ineligible for Intensive Treatment
    Maertens, Johan
    Luebbert, Michael
    Fiedler, Walter
    Fouillard, Loic
    Haaland, Alf
    Brandwein, Joseph M.
    Lepretre, Stephane
    Reman, Oumedaly
    Turlure, Pascal
    Bug, Gesine
    Mueller-Tidow, Carsten
    Kraemer, Alwin
    Voss, Florian
    Taube, Tillmann
    Fritsch, Holger
    Doehner, Hartmut
    BLOOD, 2012, 120 (21)
  • [33] High-dose radiation therapy and neoadjuvant plus concomitant chemotherapy with 5-fluorouracil and cisplatin in patients with locally advanced squamous-cell anal canal cancer:: Final results of a phase II study
    Peiffert, D
    Giovannini, M
    Ducreux, M
    Michel, P
    François, E
    Lemanski, C
    Mirabel, X
    Cvitkovic, F
    Luporsi, E
    Conroy, T
    Gérard, JP
    ANNALS OF ONCOLOGY, 2001, 12 (03) : 397 - 404
  • [34] Addition of Sorafenib to Cladribine, High-Dose Cytarabine, G-CSF, and Mitoxantrone (CLAG-M) in Adults with NewlyDiagnosed Acute Myeloid Leukemia (AML) and High-Grade Myeloid Neoplasms Independent of FLT3-Mutation Status: Final Results of a Phase 1/2 Study
    Halpern, Anna B.
    Rodriguez-Arboli, Eduardo P.
    Othus, Megan
    Garcia, Kelsey-Leigh A.
    Percival, Mary-Elizabeth M.
    Cassaday, Ryan D.
    Oehler, Vivian G.
    Becker, Pamela S.
    Appelbaum, Jacob S.
    Abkowitz, Janis L.
    Orozco, Johnnie J.
    Keel, Sioban B.
    Hendrie, Paul C.
    Scott, Bart L.
    Ghiuzeli, Cristina
    Walter, Roland B.
    Estey, Elihu H.
    BLOOD, 2022, 140 : 8999 - 9001
  • [35] Results of a multicenter phase II trial for older patients with c-kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose ara-C and imatinib
    Heidel, Florian
    Cortes, Jorge
    Ruecker, Frank G.
    Aulitzky, Walter
    Letvak, Laurie
    Kindler, Thomas
    Huber, Christoph
    Doehner, Hartmut
    Kantarjian, Hagop
    Fischer, Thomas
    CANCER, 2007, 109 (05) : 907 - 914
  • [36] LOW DOSE GEMTUZUMAB OZOGAMICIN PLUS FLUDARABINE, CYTARABINE, IDARUBICIN (GO-FLAI) AS INDUCTION THERAPY IN CD33-POSITIVE ACUTE MYELOID LEUKEMIA (AML) PATIENTS YOUNGER THAN 65 YEARS. INTERIM RESULTS FROM A PHASE III MULTICENTER PROSPECTIVE CLINICAL TRIAL (MYFLAI07NCT.00909168).
    Candoni, A.
    Martinelli, G.
    Gherlinzoni, F.
    Papayanidis, C.
    Lacobucci, I.
    Gottardi, M.
    Visani, G.
    Simeone, E.
    Paolini, S.
    Lama, B.
    Michelutti, A.
    Isidori, A.
    Piccaluga, P.
    Sparaventi, G.
    Malagola, M.
    Russo, D.
    Baccarani, M.
    Fanin, R.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 225 - 225
  • [37] DAILY LOW-DOSE CISPLATIN PLUS CONCURRENT HIGH-DOSE THORACIC IRRADIATION IN LOCALLY ADVANCED UNRESECTABLE NON-SMALL-CELL LUNG-CANCER - RESULTS OF A PHASE-II SOUTHWEST-ONCOLOGY-GROUP STUDY
    HAZUKA, MB
    CROWLEY, JJ
    BUNN, PA
    OROURKE, M
    BRAUN, TJ
    LIVINGSTON, RB
    JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (09) : 1814 - 1820
  • [38] Results of a multicenter phase II trial for older patients with c-Kit positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C (LDAC) and imatinib.
    Heidel, F
    Cortes, J
    Ruecker, F
    Kaufmann, M
    Aulitzky, W
    Letvak, L
    Kindler, T
    Huber, C
    Dohner, H
    Kantarjian, H
    Fischer, T
    BLOOD, 2005, 106 (11) : 527A - 527A
  • [39] Feasibility of Allogeneic Hematopoietic Cell Transplantation Among High-Risk AML Patients in First Complete Remission: Results of the Transplant Objective from the SWOG (S1203) Randomized Phase III Study of Induction Therapy Using Standard 7+3 Therapy or Idarubicin with High-Dose Cytarabine (IA) Versus IA Plus Vorinostat
    Pagel, John M.
    Othus, Megan
    Garcia-Manero, Guillermo
    Fang, Min
    Radich, Jerald P.
    Rizzieri, David A.
    Marcucci, Guido
    Strickland, Stephen A.
    Litzow, Mark
    Savoie, Mary Lynn
    Spellman, Stephen R.
    Confer, Dennis L.
    Chell, Jeffrey
    Brown, Maria
    Medeiros, Bruno C.
    Sekeres, Mikkael A.
    Lin, Tara L.
    Uy, Geoffrey L.
    Powell, Bayard L.
    Kolitz, Jonathan E.
    Larson, Richard A.
    Stone, Richard M.
    Claxton, David F.
    Essell, James
    Luger, Selina
    Mohan, Sanjay R.
    Moseley, Anna
    Erba, Harry P.
    Appelbaum, Frederick R.
    BLOOD, 2016, 128 (22)
  • [40] Phase II Study of Venetoclax Added to Cladribine plus Low Dose AraC (LDAC) Alternating with 5-Azacytidine Demonstrates High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) and Excellent Tolerability in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
    Kadia, Tapan M.
    Borthakur, Gautam
    Pemmaraju, Naveen
    Daver, Naval
    DiNardo, Courtney D.
    Sasaki, Koji
    Issa, Ghayas C.
    Ohanian, Maro
    Bravo, Guillermo Montalban
    Short, Nicholas J.
    Jain, Nitin
    Ferrajoli, Alessandra
    Bhalla, Kapil N.
    Jabbour, Elias
    Kanagal-Shamanna, Rashmi
    Takahashi, Koichi
    Malla, Rashmi
    Marek, Kelly
    Brandt, Mark
    Popat, Uday R.
    Andreeff, Michael
    Cortes, Jorge E.
    Garcia-Manero, Guillermo
    Konopleva, Marina
    Ravandi, Farhad
    Kantarjian, Hagop M.
    BLOOD, 2020, 136
12345